546C88
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597648

CAS#: 156706-47-7

Description: 546C88 is a nitric oxide synthase inhibitor.


Chemical Structure

img
546C88
CAS# 156706-47-7

Theoretical Analysis

MedKoo Cat#: 597648
Name: 546C88
CAS#: 156706-47-7
Chemical Formula: C7H17ClN4O2
Exact Mass:
Molecular Weight: 224.68
Elemental Analysis: C, 37.42; H, 7.63; Cl, 15.78; N, 24.94; O, 14.24

Price and Availability

Size Price Availability Quantity
50.0mg USD 530.0 2 Weeks
250.0mg USD 1660.0 2 Weeks
Bulk inquiry

Synonym: 546C88; L-NMMA; NG-Monomethyl-L-arginine hydrochloride; L-N(G)-Methylarginine hydrochloride;

IUPAC/Chemical Name: Nw-methyl-L-arginine hydrochloride

InChi Key: QYGXVJHXZUSLQC-JEDNCBNOSA-N

InChi Code: InChI=1S/C7H16N4O2.ClH/c1-10-7(9)11-4-2-3-5(8)6(12)13;/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H/t5-;/m0./s1

SMILES Code: N[C@@H](CCCNC(NC)=N)C(O)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 224.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schwartz S, Clare R, Devereux K, Sheung CF. Pharmacokinetics, disposition and metabolism of 546C88 (L-NG-methylarginine hydrochloride) in rat and dog. Xenobiotica. 1997 Dec;27(12):1259-71. PubMed PMID: 9460231.

2: Cooper JD, Shearsby N, Sheung CT. Use of the ASTED system to determine L-NG-monomethylarginine (546C88) in human plasma by pre-column o-phthalaldehyde derivatisation and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Aug 15;696(1):117-22. PubMed PMID: 9300915.

3: López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004 Jan;32(1):21-30. PubMed PMID: 14707556.

4: Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, Guntupalli K, Grossman S, Donaldson J, Le Gall JR; Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan;32(1):13-20. PubMed PMID: 14707555.

5: Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J; Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan;32(1):1-12. PubMed PMID: 14707554.

6: Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med. 1999 May;27(5):913-22. PubMed PMID: 10362413.

7: Renes MH, van der Hoeven JG. Administration of nitric oxide synthase inhibitor 546C88 in septic shock. Crit Care Med. 2004 Jul;32(7):1625; author reply 1625-6. PubMed PMID: 15241124.

8: Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, Olesen J. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia. 1998 Jan;18(1):27-32. PubMed PMID: 9601621.

9: Harrison RW, Thakkar RN, Senzaki H, Ekelund UE, Cho E, Kass DA, Hare JM. Relative contribution of preload and afterload to the reduction in cardiac output caused by nitric oxide synthase inhibition with L-N(G)-methylarginine hydrochloride 546C88. Crit Care Med. 2000 May;28(5):1263-8. PubMed PMID: 10834663.

10: Lassen Lh, Sperling B, Andersen Ar, Olesen J. The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546C88) on basal and acetazolamide (Diamox) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man. Cephalalgia. 2005 May;25(5):344-52. PubMed PMID: 15839849.

11: Hjorth Lassen L, Klingenberg Iversen H, Olesen J. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. Eur J Clin Pharmacol. 2003 Oct;59(7):499-505. Epub 2003 Sep 6. PubMed PMID: 13680036.

12: Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003 Nov;23(9):877-86. PubMed PMID: 14616929.

13: Hussein Z, Beerahee M, Grover R, Jordan B, Jeffs R, Donaldson J, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Clin Pharmacol Ther. 1999 Jan;65(1):1-9. PubMed PMID: 9951425.

546C88

50.0mg / USD 530.0